It can take 10-15 years to develop a new medicine at an estimated cost of £1.2bn
At the Medicines Discovery Catapult we aim to help UK SME biotechs, academics and innovators have access to the laboratory facilities, knowledge, data, technologies and networks they need to be able to progress their programmes of medicines research and development. Our objective is to work collaboratively as part of a Syndicate to bring new proven therapies to patients faster and more cost-effectively.
Latest News
Psychiatry Consortium launches second call for proposals
The Psychiatry Consortium is again seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions: psychotic disorders,
Medicines Discovery Catapult welcomes new Board Members
This week the Medicines Discovery Catapult has welcomed three new Board Members. Alistair Macdonald, Graham Clarke and Sue Wallcraft have joined the Medicines Discovery Catapult
Supporting the race for treatments new collaboration launched to drive understanding of COVID-19
Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19 Today (27th April) Medicines Discovery Catapult, Retrogenix and Peak Proteins announce